Alpha 2.0
Login Register
» Authors » Elizabeth Irungu

Elizabeth Irungu

Explore the profile of Elizabeth Irungu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 602
Followers 0
Related Specialties
Infectious Diseases
Health Services
General Medicine
Top 10 Co-Authors
Jared M Baeten
Nelly Mugo
Kenneth Ngure
Connie Celum
Nelly R Mugo
Jairam R Lingappa
Renee Heffron
Josephine Odoyo
Elizabeth A Bukusi
Kenneth K Mugwanya
Published In
J Int AIDS Soc
J Acquir Immune Defic Syndr
J Infect Dis
BMC Health Serv Res
AIDS
Affiliations
Soon will be listed here.
Recent Articles
1.
Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods
Bishopp C, Mungai-Barris Z, Briedenhann E, Donaldson E, Irungu E, Schwartz K
Curr HIV/AIDS Rep . 2024 Dec; 22(1):7. PMID: 39644439
Purpose Of Review: As injectable cabotegravir for pre-exposure prophylaxis (CAB PrEP) is introduced in sub-Saharan Africa, it is important to understand how behavioral drivers may influence women's decisions around whether...
2.
Computational Microbiome Pharmacology Analysis Elucidates the Anti-Cancer Potential of Vaginal Microbes and Metabolites
Lawore D, Jena S, Berard A, Birse K, Lamont A, Mackelprang R, et al.
bioRxiv . 2024 Oct; PMID: 39416028
The vaginal microbiome's role in risk, progression, and treatment of female cancers has been widely explored. Yet, there remains a need to develop methods to understand the interaction of microbiome...
3.
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
Zhang L, Iannuzzi S, Chaturvedula A, Irungu E, Haberer J, Hendrix C, et al.
Nat Med . 2023 Nov; 29(11):2753-2762. PMID: 37957377
Most human immunodeficiency virus (HIV) infections occur in cisgender women in resource-limited settings. In women, self-protection with emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP) constitutes a major pillar of HIV prevention....
4.
Prevalence of Antimicrobial Resistance and Association with Patient Outcomes in a Rural Kenyan Hospital
Drobish I, Barasa I, Otieno G, Osoo M, Thuo S, Belknap K, et al.
Am J Trop Med Hyg . 2023 May; 108(6):1227-1234. PMID: 37160272
Data on antimicrobial resistance (AMR) and association with outcomes in resource-variable intensive care units (ICU) are lacking. Data currently available are limited to large, urban centers. We attempted to understand...
5.
Vaginal epithelial dysfunction is mediated by the microbiome, metabolome, and mTOR signaling
Berard A, Brubaker D, Birse K, Lamont A, Mackelprang R, Noel-Romas L, et al.
Cell Rep . 2023 May; 42(5):112474. PMID: 37149863
Bacterial vaginosis (BV) is characterized by depletion of Lactobacillus and overgrowth of anaerobic and facultative bacteria, leading to increased mucosal inflammation, epithelial disruption, and poor reproductive health outcomes. However, the...
6.
An empiric tool to identify Kenyans living with HIV who will have unsuppressed viremia 18 months following treatment initiation to guide differentiated care models
Njuguna N, Mugo N, Anzala O, Mureithi M, Irungu E, Wamicwe J, et al.
PLoS One . 2022 Jul; 17(7):e0271520. PMID: 35853007
Background: With the global push towards universal access to Antiretroviral Treatment (ART), patient numbers are increasing, further straining already under-resourced healthcare systems in sub-Saharan Africa. A simple scoring tool could...
7.
A one-stop shop model for improved efficiency of pre-exposure prophylaxis delivery in public clinics in western Kenya: a mixed methods implementation science study
Roche S, Odoyo J, Irungu E, Kwach B, Dollah A, Nyerere B, et al.
J Int AIDS Soc . 2021 Dec; 24(12):e25845. PMID: 34898032
Introduction: In public clinics in Kenya, separate, sequential delivery of the component services of pre-exposure prophylaxis (PrEP) (e.g. HIV testing, counselling, and dispensing) creates long wait times that hinder clients'...
8.
Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research
Irungu E, Khoza N, Velloza J
Curr HIV/AIDS Rep . 2021 Nov; 18(6):490-499. PMID: 34719745
Purpose Of Review: This review summarizes interventions to promote HIV pre-exposure prophylaxis (PrEP) use among adolescent girls and young women (AGYW) in HIV endemic settings, while also highlighting gaps in...
9.
Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public sector
Peebles K, Mugwanya K, Irungu E, Odoyo J, Wamoni E, Morton J, et al.
BMC Health Serv Res . 2021 Aug; 21(1):823. PMID: 34399736
Background: In 2017, the Kenyan Ministry of Health integrated provision of pre-exposure prophylaxis (PrEP) into public HIV-1 care clinics as a key component of the national HIV-1 prevention strategy. Estimates...
10.
Differences in Vaginal Microbiota, Host Transcriptome, and Proteins in Women With Bacterial Vaginosis Are Associated With Metronidazole Treatment Response
Serebrenik J, Wang T, Hunte R, Srinivasan S, McWalters J, Tharp G, et al.
J Infect Dis . 2021 May; 224(12):2094-2104. PMID: 34003290
Background: Bacterial vaginosis (BV) treatment failures and recurrences are common. To identify features associated with treatment response, we compared vaginal microbiota and host ectocervical transcriptome before and after oral metronidazole...